Document:

Exhibit 10.2

 

August 4, 2016

 

Paul E. Freiman

7 Harbor Drive

Port Chester, NY 10573

 

Re: Director Separation Agreement

 

In connection with your resignation from
the Board of Directors of Neurotrope, Inc. (the "Company") effective as of August 4, 2016 (the “Effective Date”),
you and the Company have agreed to the following:

 

1.           Vesting and Exercisability of Stock
Options. On the Effective Date, (i) all unvested options under all of the Stock Option Agreements between the Company and you
shall immediately vest, automatically and without any further action by the parties hereto notwithstanding that you, on the previously
scheduled vesting dates, may no longer be a director or service provider to the Company, and (ii) all vested options (including
those whose vesting occurs pursuant the preceding clause) under all of the Stock Option Agreements between the Company and you
(including, without limitation, the options set forth on Schedule A) shall continue to be exercisable for a period of ten (10)
years following the respective dates of grant.

 

2.           Press Releases and Communications.
Both the Company and you shall have mutual consent rights over any press releases, public communications and references to you
in the Company’s securities filings, relating to your resignation from the Board of Directors of the Company. You agree that
you will not make or cause to be made any disparaging or negative statements about the Company or any of its directors, officers
or employees, and the Company agrees that it will not, and it will direct its directors and officers not to, make any disparaging
or negative statements about you.

 

3.           Mutual Releases. (a) You, on
behalf of yourself and your heirs, personal representatives, successors and assigns, hereby release, discharge and waive any and
all claims, counterclaims, actions or causes of action whether asserted or unasserted and whether known or unknown which you, he,
she or they have possessed or may possess up until the time of the Effective Date against the Company and its affiliates, and covenants
not to sue any of them for any of such claims, excepting from such release (1) the terms and conditions of this Agreement and documents
contemplated to be delivered hereby, (2) continued indemnification under the Company’s Certificate of Incorporation, By-Laws,
and applicable law, (3) continued coverage as a named insured under all of the Company’s D&O insurance policies, (4)
all rights under stock option and stock award agreements, shareholder, registration rights, investor rights and similar agreements
to which Executive and the Company are a party, and (5) all rights as a shareholder of the Company, and (b) effective on the Effective
Date, and excepting only the terms and conditions of this Agreement and the documents contemplated to be delivered hereby, the
Company, on behalf of itself and its affiliates and its and their successors and assigns, hereby releases, discharges and waives
any and all claims, counterclaims, actions and causes of action whether asserted or unasserted and whether known or unknown which
it, he or they may have possessed or may possess up until the time of the Effective Date against you, and your heirs, personal
representatives, successors and assigns, including without limitation, any claims in any way related to your acts or omissions
as a director of the Company, or any possible legal, equitable, contract or tort claim, whether based on breach of contract, fraud,
libel, slander, tortious interference with business relations or otherwise, and covenants not to sue any of them for any such claims.
Notwithstanding the foregoing, the Company’s release of you shall not include any claims arising out of or relating to any
of your conduct that is criminal or fraudulent as determined in a final non-appealable judgment.

 

     

     

    

 

Neurotrope, Inc.

 

August 4, 2016

Page 2

 

 

This agreement may be executed in any number
of counterparts, which together shall constitute this agreement. This agreement shall be governed by, and construed in accordance
with, the laws of the State of New York (without giving effect to the conflict of laws principles thereof). Any amendments or modifications
hereto must be executed in writing by all parties.

 

 

[Signature Page Follows]

 

 

 

     

     

    

 

Neurotrope, Inc.

 

August 4, 2016

Page 3

 

 

If the foregoing correctly
sets forth our agreement and understanding, please indicate your acceptance of the foregoing by signing and returning to me a copy
of this agreement.

 

	 	Very truly yours,	 
	 	 	 	 
	 	NEUROTROPE, INC.	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Robert Weinstein	 
	 	Name: Robert Weinstein	 
	 	Title: Chief Financial Officer	 

 

Accepted and Agreed:

 

 

	Name: 	/s/ Paul E. Freiman	 
	 	Paul E. Freiman	 
	 	 	 
	Date: 	August 4, 2016Exhibit 10.3

 

August 4, 2016

 

Jay M. Haft

110 East 57th Street, Apartment 14A

New York, NY 10022

 

Re: Director Separation Agreement

 

In connection with your resignation from
the Board of Directors of Neurotrope, Inc. (the "Company") effective as of August 4, 2016 (the “Effective Date”),
you and the Company have agreed to the following:

 

1.           Vesting and Exercisability of Stock
Options. On the Effective Date, (i) all unvested options under all of the Stock Option Agreements between the Company and you
shall immediately vest, automatically and without any further action by the parties hereto notwithstanding that you, on the previously
scheduled vesting dates, may no longer be a director or service provider to the Company, and (ii) all vested options (including
those whose vesting occurs pursuant the preceding clause) under all of the Stock Option Agreements between the Company and you
(including, without limitation, the options set forth on Schedule A) shall continue to be exercisable for a period of ten (10)
years following the respective dates of grant.

 

2.           Press Releases and Communications.
Both the Company and you shall have mutual consent rights over any press releases, public communications and references to you
in the Company’s securities filings, relating to your resignation from the Board of Directors of the Company. You agree that
you will not make or cause to be made any disparaging or negative statements about the Company or any of its directors, officers
or employees, and the Company agrees that it will not, and it will direct its directors and officers not to, make any disparaging
or negative statements about you.

 

3.           Mutual Releases. (a) You, on
behalf of yourself and your heirs, personal representatives, successors and assigns, hereby release, discharge and waive any and
all claims, counterclaims, actions or causes of action whether asserted or unasserted and whether known or unknown which you, he,
she or they have possessed or may possess up until the time of the Effective Date against the Company and its affiliates, and covenants
not to sue any of them for any of such claims, excepting from such release (1) the terms and conditions of this Agreement and documents
contemplated to be delivered hereby, (2) continued indemnification under the Company’s Certificate of Incorporation, By-Laws,
and applicable law, (3) continued coverage as a named insured under all of the Company’s D&O insurance policies, (4)
all rights under stock option and stock award agreements, shareholder, registration rights, investor rights and similar agreements
to which Executive and the Company are a party, and (5) all rights as a shareholder of the Company, and (b) effective on the Effective
Date, and excepting only the terms and conditions of this Agreement and the documents contemplated to be delivered hereby, the
Company, on behalf of itself and its affiliates and its and their successors and assigns, hereby releases, discharges and waives
any and all claims, counterclaims, actions and causes of action whether asserted or unasserted and whether known or unknown which
it, he or they may have possessed or may possess up until the time of the Effective Date against you, and your heirs, personal
representatives, successors and assigns, including without limitation, any claims in any way related to your acts or omissions
as a director of the Company, or any possible legal, equitable, contract or tort claim, whether based on breach of contract, fraud,
libel, slander, tortious interference with business relations or otherwise, and covenants not to sue any of them for any such claims.
Notwithstanding the foregoing, the Company’s release of you shall not include any claims arising out of or relating to any
of your conduct that is criminal or fraudulent as determined in a final non-appealable judgment.

  

     

     

    

 

Neurotrope, Inc.

 

August 4, 2016

Page 2

 

 

This agreement may be executed in any number
of counterparts, which together shall constitute this agreement. This agreement shall be governed by, and construed in accordance
with, the laws of the State of New York (without giving effect to the conflict of laws principles thereof). Any amendments or modifications
hereto must be executed in writing by all parties.

 

 

[Signature Page Follows]

 

 

 

     

     

    

 

Neurotrope, Inc.

 

August 4, 2016

Page 3

 

If the foregoing correctly
sets forth our agreement and understanding, please indicate your acceptance of the foregoing by signing and returning to me a copy
of this agreement.

 

	 	Very truly yours,	 
	 	 	 	 
	 	NEUROTROPE, INC.	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Robert Weinstein	 
	 	Name: Robert Weinstein	 
	 	Title: Chief Financial Officer	 

 

Accepted and Agreed:

  

 

	Name: 	/s/ Jay M. Haft	 
	 	Jay M. Haft	 
	 	 	 
	Date: 	August 4, 2016Exhibit 10.4

 

COMPANY CONSULTING AGREEMENT

 

CONSULTING AGREEMENT
effective as of August 4, 2016 between NEUROTROPE, INC., a Nevada corporation, having a mailing address at 50 Park Place, Suite
1401, Newark, New Jersey 07102 (the “Company”) and SM CAPITAL MANAGEMENT, LLC, a Delaware limited liability company
(“Consultant”).

 

WITNESSETH:

 

WHEREAS, the Company
is engaged in the research, design and development, of proprietary technologies and pharmaceuticals for the diagnosis and treatment
of Alzheimer’s Disease and licenses, owns and controls intellectual property relating thereto;

 

WHEREAS, Consultant
is owned and controlled by Joshua Silverman;

  

WHEREAS, in view of
Mr. Silverman’s financial and corporate governance expertise and experience in designing and executing complex, value-accretive
transactions, the Company desires to retain Consultant to provide consulting services to the Company, all upon the terms and subject
to the conditions hereinafter set forth;

 

NOW, THEREFORE,
in consideration of the mutual premises, covenants and agreements set forth below and intending to be legally bound, the parties
hereto agree as follows:

 

1.           Retention
of Consultant; Term. (a) The Company hereby agrees to retain the Consultant, and the Consultant hereby agrees to serve,
as an independent consultant to the Company, in accordance with the terms and provisions of this Agreement, during the Consulting
Term. The Consulting Term shall initially be set at one- year from the date of this Agreement, and thereafter, will be automatically
renewed from year to year on August 4th of each year, without any further action by the parties, unless either the Company or Consultant
notifies the other party in writing at least thirty (30) days prior to the expiration of the Consulting Term then in effect that
it does not desire to renew this Agreement

 

(b)           The
Company may terminate the Consulting Term for “Cause”, upon thirty (30) days written notice describing the circumstances
thereof in reasonable detail (during which time Consultant shall have the opportunity to explain the situation and correct any
misunderstandings). As used herein, the term “Cause” shall mean: (i) any material breach of this Agreement by the Consultant;
(ii) any willful or gross neglect by the Consultant of his duties and responsibilities hereunder; (iii) any fraud, criminal misconduct,
breach of fiduciary duty, dishonesty, gross negligence or willful misconduct by the Consultant in connection with the performance
of his duties and responsibilities hereunder; (iv) the commission by the Consultant of any (A) felony or (B) crime or act of moral
turpitude; (v) any action by the Consultant that may materially impair or damage the reputation of the Company; (vi) insubordinate
disregard of any lawful direction given to the Consultant by the Board; or (viii) failure or refusal to comply with the Company’s
lawful policies and procedures.

  

(c)           Consultant
may terminate the Consulting Term for “Good Reason”. For purposes of this Agreement, “Good Reason” shall
mean that the Company has failed to pay Consultant any compensation or reimbursements due to Consultant under Sections 3 or 4 of
this Agreement, or the Company has breached any of its representations, warranties or covenants under this Agreement, or the Company
or its management has engaged in willful and intentional acts of fraud or illegal activity involving the Company, and any such
failure, breach or default continues uncured after ten (10) days written notice from Consultant to the Company describing the circumstances
thereof in reasonable detail (during which time the Company shall have the opportunity to explain the situation and correct any
misunderstandings).

 

2.           Consulting
Services of Consultant.

 

(a)           Consultant
shall make available Mr. Silverman to provide consulting services for the Company, on a part-time basis, although there is no minimum
time commitment. The consulting services to be performed by Consultant as an independent consultant to the Company during
the Consulting Term shall include, but not be limited to, providing business development, financial communications and management
transition services.

 

     

     

    

 

(b)           Mr.
Silverman may provide services either from his own home or offices, or via telephone or video conference calls, emails, text, or
other methods of communication. Mr. Silverman will render services from New York except upon Company approved and reimbursed travel
to the Company’s facilities. Consulting services which shall count towards Mr. Silverman’s obligations shall include
time spent at meetings, presentations and calls and on research and analysis relating to the Company, regardless of location, as
well as travel time, whether out of town or locally. Mr. Silverman may schedule services to the Company, at their mutual convenience,
and the Company recognizes that there may be weeks when Mr. Silverman is traveling on vacation or other business and work for the
Company will be rescheduled for other times.

 

(c)           Mr.
Silverman shall maintain any such information provided to him regarding the Company which is non-public and proprietary in confidence
and shall not use, disclose or transfer such information for purposes competitive or adverse to the Company. However, the Company
acknowledges that Mr. Silverman’s services with respect to the Company include attending and participating in meetings, calls
and communications and providing information regarding the Company in presentations and negotiations, with professional advisors,
investors, lenders, underwriters, customers, joint venturers, licensees, consultants, contractors and other counterparties of the
Company, and any of such Mr. Silverman’s activities on behalf of the Company shall be permissible. Further, Consultant shall
be entitled to disclose such Company information in response to court orders, subpoenas and other legal process, after notifying
the Company of such requests so the Company has the opportunity to challenge or limit such request.

 

3.           Consulting
Fees.           (b) As compensation for the services to be rendered
by Consultant pursuant to this Agreement during the Consulting Term, the Company agrees to pay to Consultant a monthly fee of Ten
Thousand Dollars ($10,000), to be wire transferred to Consultant’s account on or before the first day of each calendar month
(with the first such payment to be made within two (2) business days of the execution of this Agreement).

 

(b)           Since
the Consultant is an independent contractor of the Company and not an employee, there will be no withholding for taxes from any
payments due to Consultant under this Agreement.

 

4.           Reimbursement
of Expenses.

 

(a)           Consultant shall
be reimbursed for all pre-approved travel in connection with the Consultant’s services to the Company, including without
limitation, any travel to the Company’s facilities.

 

(b)          Consultant
shall also be reimbursed, upon submission to the Company of appropriate vouchers and receipts, for all other out-of-pocket expenses
reasonably incurred by Consultant in furtherance of the Company’s business.           

  

(c)          Such
reimbursements shall be paid promptly after the required submissions, and in no event less frequently than monthly.

 

(d)          The Company agrees
to reimburse Consultant’s out-of-pocket legal and advisory fees in connection with Consultant’s recent proposed consent
solicitation with respect to the Company, including, but not limited to, expenses incurred in connection with this Agreement, which
reimbursement shall not exceed $50,000.

 

5.           Survival
of Payment Obligations After any Termination.

 

In the event of any
termination or expiration of the Consulting Term or this Agreement, the Company shall remain obligated and shall pay to Consultant,
within ten (10) business days of the termination or expiration date, (i) all unpaid monthly compensation through the termination
date and (ii) all unreimbursed expenses payable to Consultant pursuant to Section 4 above.

 

     

     

    

 

6.           No
Joint Venture, Etc.

 

(a)           The
Consultant and the Company shall be independent contractors and nothing in this Agreement shall be construed as creating a partnership,
joint venture, employment or agency relationship between the Company or Consultant.

 

(b)           Consultant
does not represent, warrant, guarantee or ensure any particular business results from the services which may be performed for the
Company pursuant to this Agreement.

 

(c)           In
the event that Consultant refers or introduces to the Company, or arranges for the Company to utilize the services of, third parties
such as attorneys, accountants, investment bankers, brokers, finders, sales or marketing representatives, contractors or other
consultants, such third parties will be direct contractors for the Company and not Consultant and their fees, commissions, disbursements
and other charges will be the sole responsibility of the Company. Consultant is not providing any licensed professional services
under this Agreement and the Company shall retain and rely upon its own attorneys, accountants, tax advisors, securities broker
dealers, underwriters, engineers, appraisers and other licensed professionals.

 

(d)           The
Company acknowledges that, in connection with Consultant’s performance of its services hereunder, Consultant and Mr. Silverman
at all times is entitled to rely, as to accuracy and completeness, upon information furnished to them by the Company’s directors,
officers, employees, professional advisors and agents.

 

(e)           Neither
Consultant nor any of his affiliates assumes, assures, endorses or guarantees or shall have any responsibility for any liability,
obligation or contract of the Company.

 

(f)           The
Company does hereby indemnify Consultant, Mr. Silverman and their heirs, personal representatives, successors and assigns (“Consultant
Indemnified Parties”) and agree to defend and hold them harmless from and against any and all claims, damages, charges, liabilities,
losses, judgments, fines, penalties, amounts paid in settlement or satisfaction of claims, costs and expenses (including without
limitation reasonable attorneys’ fees and expenses) arising out of, relating to or accruing in respect of (i) liabilities
and obligations of the Company or its business, products or assets, and claims relating to the conduct of the Company’s business,
including, without limitation, liabilities for taxes, regulatory fines, assessments and penalties, and any claims or disputes of
the Company with customers, doctors, patients, hospitals or other medical providers, insurers, investors, lenders, licensees, licensors,
consultants, contractors, employees or others and (ii) any breach or violation of any representation, warranty, covenant or obligation
of the Company under this Agreement. The rights of indemnification provided by this Section 6(f) shall be in addition to, and not
be deemed exclusive of, any other rights and remedies apart from this Agreement which may be available to Consultant, whether pursuant
to the Share Purchase Agreement or by any other contract, at law, in equity or otherwise.

 

7.           Member
of the Board of Directors; Chairman of the Board; Chairman of the Audit Committee; Right to Nominate an Additional Member to the
Board of Directors.           

 

(a)           Effective immediately,
Mr. Silverman shall be appointed as a member of the Board of Directors (the “Board”) of the Company, and such appointment
shall be ratified as of the date of this Agreement. Mr. Silverman shall continue to be a member of the Board of the Company throughout
the Consulting Term.

 

(b)           As
promptly as practicable following the execution of this Agreement, the Board and all applicable committees of the Board shall take
all necessary actions to appoint Mr. Silverman as Chairman of the Board and as Chairman of the Audit Committee of the Board. Mr.
Silverman shall continue to serve as Chairman of the Board and Chairman of the Audit Committee throughout the Consulting Term provided
that Mr. Silverman qualifies to serve on such committee under any applicable federal securities laws and securities exchange rules
and regulations.

 

(c)           The
Company will indemnify Mr. Silverman to the fullest and same extent as the Company provides indemnification to its Directors from
time to time under the Company’s Certificate of Incorporation, By-Laws and applicable law, and under the Company’s
policies of Directors and Officers Liability Insurance. The Company will take steps to assure that Mr. Silverman is covered by
the Company’s policies of Directors and Officers Liability Insurance.

 

     

     

    

 

(d)           The
Company will provide compensation to Mr. Silverman in the same amounts as the Company provides to its non-employee Directors for
service in the capacity of a Director.

 

(e)           The Company shall
take all actions within its control, including the recommendation of such director nominee by the Nominating and Governance Committee
of the Board, to nominate and appoint one (1) additional member to the Board designated by Josh Silverman during the initial consulting
term.

 

8.           Notices.
Any notices and other communications hereunder shall be in writing and shall be deemed to have been duly given when mailed by first
class registered or certified, postage prepaid, to their addresses as set forth above, or by courier delivery or by fax or email
with confirmed receipt, or to such other address as shall be designated by such party by notice given in accordance herewith.

 

Copies of all notices
to the Company shall be sent to

 

Robert Weinstein

Chief Financial Officer

Neurotrope, Inc.

50 Park Place, Suite 1401

Newark, New Jersey 07102

Tel: 917.837.4543

Email: rweinstein@neurotropebioscience.com

 

Copies of all notices
to the Consultant shall be sent to

 

Andrew Freedman, Esq.

Olshan Frome Wolosky
LLP

1325 Avenue of the Americas

New York, New York 10019

Tel: (212) 451-2250

Fax: (212) 451-2222

Email: afreedman@olshanlaw.com

 

9.           General
Provisions.

 

(a)           Any
provision of this Agreement which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective
to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition
or unenforceability in any jurisdiction shall not be invalidate or render unenforceability such provision in any other jurisdiction.

 

(b)           No
failure to exercise nor any delay in exercising on the part of any party of any right, power or privilege hereunder shall operate
as a waiver thereof; not shall any single or partial exercise of any right, power or privilege hereunder preclude any other or
further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided are cumulative
and may be exercised singly or concurrently, and are not exclusive of any rights or remedies provided by law.

 

(c)           None
of the terms or provisions of this Agreement may be waived, altered, modified or amended except by an instrument in writing, duly
executed by Consultant and the Company. This Agreement shall inure to the benefit of and be enforceable by and binding upon Consultant
and the Company and their respective heirs, personal representatives, successors and assigns. Neither the Company nor Consultant
shall transfer or assign their rights or obligations under this Agreement.

 

(d)           Each
of the parties hereto shall cooperate and take such actions, and execute such other documents and instruments, as may be reasonably
requested by the others in order to carry out the provisions and purposes of this Agreement.

 

     

     

    

 

(e)           This
Agreement may be executed in counterpart copies and each of which shall be an original but all of which shall constitute a single
instrument.

 

(f)           The
provisions and covenants set forth in this Agreement are for the benefit of the parties to this Agreement and not for the benefit
of any third party or other person, and no third party or other person shall have any right to enforce the provisions and covenants
against any party hereto.

 

(g)           This
Agreement shall be construed and governed by the laws of the State of New York. Each party hereto for himself, itself and his or
its heirs, personal representatives, successors and assigns, hereby consents to personal jurisdiction over him, it and them in
the federal and state courts located in the State of New York. The Consultant may enforce this Agreement both in New York and any
state where the Company is located.

 

(h)           The
Company represents and warrants to Consultant that this Agreement has been duly authorized by all necessary corporate action, has
been duly executed and delivered and constitutes the legal, valid and binding obligation of the Company enforceable in accordance
with its terms.

 

(i)           The
Company will require any successor (whether direct or indirect, by purchase of assets or capital stock, merger, consolidation or
otherwise) to all or substantially all of the business and/or assets of the Company to assume expressly and agree in writing to
perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession
had taken place. As used in this Agreement, the “Company” shall mean the Company as hereinabove defined and any successor
to its business and/or assets as aforesaid which assumes and agrees to perform this Agreement by operation of law or otherwise.           

 

     

     

    

  

IN WITNESS WHEREOF,
the Company and Consultant have caused this Agreement to be executed as of the day and year first above written.           

 

	 	NEUROTROPE, INC.

 

	 	By:	 /s/ Robert Weinstein

 

	 	Printed Name: 	Robert Weinstein

 

	 	Title:	 Chief Financial Officer

 

 

	 	SM CAPITAL MANAGEMENT, LLC
	 	 	 
	 	By:	/s/ Joshua Silverman
	 	 	Joshua Silverman, Managing Member

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}]]